What is she best known for?
The fields of study she is best known for:
- Dopamine
- Neurotransmitter
- Internal medicine
Annalisa Pinna focuses on Pharmacology, Parkinson's disease, Dopamine, Internal medicine and Endocrinology.
Her research integrates issues of Amphetamine, Hydroxydopamine and Clinical trial in her study of Pharmacology.
Annalisa Pinna focuses mostly in the field of Parkinson's disease, narrowing it down to topics relating to Receptor and, in certain cases, Neuroprotection.
Her Dopamine research is classified as research in Neuroscience.
Her study in Agonist, Dopamine receptor and Adenosine A3 receptor is carried out as part of her Internal medicine studies.
Her biological study spans a wide range of topics, including Nigrostriatal pathway and Adenosine.
Her most cited work include:
- Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. (153 citations)
- Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats (142 citations)
- Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease (135 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Dopamine, Internal medicine, Endocrinology, Pharmacology and Parkinson's disease.
Her Dopamine research is within the category of Neuroscience.
Her work on Dopamine receptor, Nucleus accumbens and SCH-23390 as part of general Endocrinology study is frequently linked to c-Fos, bridging the gap between disciplines.
In her study, SCH-58261 and Antagonist is inextricably linked to Adenosine A2A receptor, which falls within the broad field of Pharmacology.
Her Parkinson's disease research integrates issues from Receptor, Clinical trial, Adenosine and Neuroprotection.
Her study in the fields of Nigrostriatal pathway under the domain of Dopaminergic overlaps with other disciplines such as Transmission.
She most often published in these fields:
- Dopamine (53.21%)
- Internal medicine (44.04%)
- Endocrinology (44.04%)
What were the highlights of her more recent work (between 2013-2021)?
- Dopamine (53.21%)
- Pharmacology (34.86%)
- Parkinson's disease (33.94%)
In recent papers she was focusing on the following fields of study:
Annalisa Pinna mainly focuses on Dopamine, Pharmacology, Parkinson's disease, Neuroscience and Substantia nigra.
Annalisa Pinna specializes in Dopamine, namely Dopamine receptor D1.
Her Parkinson's disease research includes elements of Receptor, Adenosine A2A receptor, Adenosine receptor and Adenosine.
A large part of her Neuroscience studies is devoted to Dopaminergic.
Her Substantia nigra research incorporates elements of Striatum, Neuroprotection, Ventral tegmental area and Tyrosine hydroxylase.
Annalisa Pinna has begun a study into Pars compacta, looking into Endocrinology and Internal medicine.
Between 2013 and 2021, her most popular works were:
- Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials From the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued (122 citations)
- l-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus (57 citations)
- l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies (57 citations)
In her most recent research, the most cited papers focused on:
- Dopamine
- Neurotransmitter
- Internal medicine
Her primary areas of investigation include Pharmacology, Neuroprotection, Parkinson's disease, Dopamine and Substantia nigra.
Her study in Pharmacology is interdisciplinary in nature, drawing from both Cannabinoid receptor antagonist and Rimonabant.
The concepts of her Cannabinoid receptor antagonist study are interwoven with issues in Endocrinology and Receptor antagonist.
The study incorporates disciplines such as Adenosine A2A receptor and Pars compacta in addition to Neuroprotection.
Her Dopamine study is related to the wider topic of Neuroscience.
Her research in Preladenant intersects with topics in Agonist, Clinical trial and Abnormal involuntary movement.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
